Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 3/20 | 0.46 |
| ▸ | FNTB | P49356 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585345 | 0.90 | ALOX15 (0.59) | ALDH1A1ALOX15TSHRGABRR1CYP1A2 | |
| SCHEMBL1871400 | 0.87 | LTA4H (0.48) | ALDH1A1ALOX15TSHRGABRR1CYP1A2 | |
| SCHEMBL11620221 | 0.85 | BLM (0.61) | ALDH1A1ALOX15TSHRGABRR1CYP1A2 | |
| SCHEMBL11617610 | 0.85 | BLM (0.61) | ALDH1A1ALOX15TSHRGABRR1CYP1A2 | |
| SCHEMBL11869803 | 0.84 | ALOX15 (0.50) | ALDH1A1ALOX15TSHRFNTAFNTB | |
| SCHEMBL9808075 | 0.81 | GABRR1 (0.43) | ALDH1A1ALOX15GABRR1CYP1A2FNTA | |
| SCHEMBL9808071 | 0.81 | GABRR1 (0.43) | ALDH1A1ALOX15GABRR1CYP1A2FNTA | |
| SCHEMBL18879326 | 0.80 | ALOX15 (0.52) | ALDH1A1ALOX15TSHRFNTAFNTB | |
| SCHEMBL6050618 | 0.80 | ALOX15 (0.52) | ALDH1A1ALOX15TSHRFNTAFNTB | |
| SCHEMBL28167129 | 0.79 | ALOX15 (0.50) | ALDH1A1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096734-A1 | MICROCAPSULES | FMC CORPORATION (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-3231789-A1 | BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF | Phenomenome Discoveries Inc. (CA) | 2017-10-18 | — | — | EP | disclosed |
| US-9783520-B2 | Macrocyclic compounds, polymers, and methods for making same | P2 SCIENCE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783520-B2 | Macrocyclic compounds, polymers, and methods for making same | P2 SCIENCE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2682746-B1 | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states | PHENOMENOME DISCOVERIES INC (CA) | 2017-05-24 | — | — | EP | disclosed |
| US-20170088536-A1 | MACROCYCLIC COMPOUNDS, POLYMERS, AND METHODS FOR MAKING SAME | P2 SCIENCE, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088536-A1 | MACROCYCLIC COMPOUNDS, POLYMERS, AND METHODS FOR MAKING SAME | P2 SCIENCE, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160377623-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| WO-2015191706-A1 | TERPENE-DERIVED COMPOUNDS AND METHODS FOR PREPARING AND USING SAME | P2 SCIENCE, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015175978-A1 | MACROCYCLIC COMPOUNDS, POLYMERS, AND METHODS FOR MAKING SAME | P2 SCIENCE, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2644588-A2 | Biomarkers for diagnosing multiple sclerosis, and methods thereof | Phenomenome Discoveries Inc. (CA) | 2013-10-02 | — | — | EP | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| US-20100062472-A1 | BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF | PHENOMENOME DISCOVERIES INC. (CA) | 2010-03-11 | — | — | US | disclosed |
| US-20100062472-A1 | BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF | PHENOMENOME DISCOVERIES INC. (CA) | 2010-03-11 | — | — | US | disclosed |
| WO-2007137410-A1 | BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF | PHENOMENOME DISCOVERIES INC. (CA) | 2007-12-06 | — | — | WO | disclosed |
| US-7247697-B2 | Coating compositions for use in golf balls | ACUSHNET COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060089419-A1 | Coating compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088536-A1 | MACROCYCLIC COMPOUNDS, POLYMERS, AND METHODS FOR MAKING SAME | PORCN, COASY, MCCC2 | ALDH1A1 3625/4885ALOX15 590/4885TSHR 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.